Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 113

Drug Profile

BNT 113

Alternative Names: BNT-113; E6/E7 RNA(LIP); HPV Anti-CD40 RNA Vaccine; HPV mRNA vaccine; RBLO 15.1(LIP)/RBLO 16.1(LIP)

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I/II Cervical cancer; Penile cancer

Most Recent Events

  • 12 Jul 2021 Biomarkers information updated
  • 30 Mar 2021 BioNTech plans phase II trials for Squamous cell carcinoma (Combination therapy, First-line therapy) in USA and the European Union (IV) in first half of 2021
  • 16 Mar 2021 Phase I/II development in Cervical cancer, Squamous cell carcinoma and Penile cancer is ongoing in United Kingdom (IV) (NCT03418480) (EudraCT 2014-002061-30)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top